Table.
Restricted Mean Survival Time to Interpret the Effect of Pravastatin vs Usual Care in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial—Lipid-Lowering Trial Primary Prevention Cohort
| Outcome | Pravastatin (95% CI) |
Usual Care (95% CI) |
Difference (95% CI) |
Interpretation |
|---|---|---|---|---|
| Overall survival | N=1466 | N=1400 | ||
| 6-y RMST, d | 2008.1 (1984.6, 2030.9) |
2041.8 (2019.3, 2063.5) |
−33.7 (−67.0, −0.5) |
Pravastatin-treated patients lived, on average, 33.7 fewer days (67.0 to 0.5 fewer days) than usual-care patients over 6 years (p=0.047). |
| 10-y RMST,a d | 3061.8 (2991.0, 3132.8) |
3169.9 (3095.7, 3234.5) |
−108.1 (−204.5, −14.1) |
Pravastatin-treated patients lived, on average, 108.1 fewer days (204.5 to 14.1 fewer days) than usual-care patients over 10 years (p=0.028). |
|
| ||||
| CHD-free survival | N=1543 | N=1387 | ||
| 6-y RMST, d | 2088.1 (2064.8, 2107.3) |
2069.4 (2048.5, 2090.3) |
18.7 (−10.4, 47.8) |
Pravastatin-treated patients lived, on average, 18.7 more days (10.4 fewer days to 47.8 more days) free of CHD than usual-care patients over 6 years (p=0.209). |
| 10-y RMST,a d | 3378.6 (3323.9, 3431.3) |
3300.7 (3239.3, 3359.2) |
77.9 (3.8, 159.6) |
Pravastatin-treated patients lived, on average, 77.9 more days (3.8 to 159.6 more days) free of CHD than usual-care patients over 10 years (p=0.046). |
Abbreviations: CHD, coronary heart disease; d, days; RMST, restricted mean survival time; y, years.
a
The 10-year restricted mean survival time was estimated from parametric Weibull survival models that were fit based on the reconstructed data.